Journal
TRENDS IN CANCER
Volume 7, Issue 2, Pages 98-111Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2020.09.007
Keywords
-
Categories
Funding
- Austrian Academy of Sciences [25524]
- Marie Sklodowska-Curie Individual Fellowship of the European Commission [843630 REAP]
- Synergy Grant of the European Research Council [855741]
- Austrian Academy of Sciences
Ask authors/readers for more resources
Targeted cancer therapies focusing on POLQ, an error-prone translesion polymerase involved in DNA repair, represent a promising approach in personalized cancer treatment. Inhibition of POLQ, currently under development, shows potential for more effective cancer therapies in the future.
Targeted cancer therapies represent a milestone towards personalized treatment as they function via inhibition of cancer-specific alterations. Polymerase theta (POLQ), an error-prone translesion polymerase, also involved in DNA double-strand break (DSB) repair, is often upregulated in cancer. POLQ is synthetic lethal with various DNA repair genes, including known cancer drivers such as BRCA1/2, making it essential in homologous recombination-deficient cancers. Thus, POLQ represents a promising target in cancer therapy and efforts for the development of POLQ inhibitors are actively underway with first clinical trials due to start in 2021. This review summarizes the journey of POLQ from a backup DNA repair enzyme to a promising therapeutic target for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available